Vor Biopharma VOR Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $17.6M-8.3% | $19.19M+35.7% | $14.14M-94.6% | $261.5M+879% | $26.7M+5.3% | ||
| $17.57M+4.7% | $16.77M+20.1% | $13.97M+9.2% | $12.79M+94.0% | $6.59M+10.5% | ||
| $35.16M-2.2% | $35.96M+27.9% | $28.11M-89.8% | $274.28M+724% | $33.29M+6.3% | ||
| $35.16M-2.2% | $35.96M+27.9% | $28.11M-89.8% | $274.28M+724% | $33.29M+6.3% | ||
| -$35.16M+2.2% | -$35.96M-27.9% | -$28.11M+89.8% | -$274.28M-724% | -$33.29M-6.3% | ||
| $3.94M+40.8% | $2.8M+61.5% | $1.73M+222% | $537K-33.3% | $805K+34.4% | ||
| -$184.43M— | —— | -$784.58M+39.6% | -$1.3B-161,514% | $805K+34.4% | ||
| -$219.59M— | —— | -$812.68M+48.4% | -$1.57B-4,744% | -$32.49M-5.8% | ||
| -$5.11— | —— | -$121.63-868% | -$12.56-141% | -$5.21+40.7% | ||
| -$5.11— | —— | -$121.63-868% | -$12.56-141% | -$5.21+40.7% | ||
| 43M+336% | 9.9M+47.7% | 6.7M-94.7% | 125.3M+1,907% | 6.2M+81.7% | ||
| 43M+336% | 9.9M+47.7% | 6.7M-94.7% | 125.3M+1,907% | 6.2M+81.7% | ||
| -$220.33M— | —— | -$812.69M+48.4% | -$1.57B-4,744% | -$32.49M-5.6% | ||
| -$747K-2,676% | $29K+1,550% | -$2K+77.8% | -$9K-1,000% | $1K— | ||
| —— | $2K-100.0% | $4.15M— | —— | —— | ||
| -$35.16M+2.2% | -$35.96M-27.9% | -$28.11M+89.8% | -$274.28M-724% | -$33.29M-6.3% | ||
| -$35.13M+2.2% | -$35.94M-27.9% | -$28.11M+89.7% | -$272.18M-738% | -$32.47M-6.6% | ||
| -$35.13M+2.2% | -$35.94M-27.9% | -$28.11M+89.7% | -$272.18M-738% | -$32.47M-6.6% | ||
| -$35.16M+2.2% | -$35.96M-27.9% | -$28.11M+89.8% | -$274.28M-724% | -$33.29M-6.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Vor Biopharma profitable?
- Vor Biopharma is not currently profitable: it reported a net loss of $2.6B over the trailing twelve months.
- What is Vor Biopharma's earnings per share?
- Vor Biopharma's diluted EPS over the trailing twelve months is $-144.51.
- Where does Vor Biopharma's income statement data come from?
- Every line is extracted from Vor Biopharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.